|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0011109,
umls-concept:C0023473,
umls-concept:C0030705,
umls-concept:C0031809,
umls-concept:C0181090,
umls-concept:C0302350,
umls-concept:C0302614,
umls-concept:C0596988,
umls-concept:C1519595,
umls-concept:C1522577,
umls-concept:C1548787,
umls-concept:C1552913,
umls-concept:C1706050,
umls-concept:C1709707,
umls-concept:C1977882
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2005-7-25
|
|
pubmed:abstractText |
Quantitative monitoring of imatinib mesylate (IM)-resistant, mutated BCR-ABL(+) cells during the follow-up of CML could be useful for optimizing therapeutic management. We retrospectively analyzed T315I mutated BCR-ABL clones throughout the CML history of two patients by nested-PCR-RFLP. At the time of progression, the T315I mutation represented 100% of the BCR-ABL transcripts. During follow-up, we showed that (i) despite a molecular response to IM, a high proportion of T315I transcripts were present (>85%) and predictive of relapse, (ii) interruption of IM and switching to other therapies resulted in a significant reduction in mutant transcript level while total BCR-ABL(+) transcripts remained stable.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0145-2126
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1073-7
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16038734-Base Sequence,
pubmed-meshheading:16038734-DNA Primers,
pubmed-meshheading:16038734-Drug Monitoring,
pubmed-meshheading:16038734-Follow-Up Studies,
pubmed-meshheading:16038734-Fusion Proteins, bcr-abl,
pubmed-meshheading:16038734-Humans,
pubmed-meshheading:16038734-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:16038734-Mutation,
pubmed-meshheading:16038734-Piperazines,
pubmed-meshheading:16038734-Polymerase Chain Reaction,
pubmed-meshheading:16038734-Polymorphism, Restriction Fragment Length,
pubmed-meshheading:16038734-Pyrimidines,
pubmed-meshheading:16038734-RNA, Messenger,
pubmed-meshheading:16038734-Retrospective Studies
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients.
|
|
pubmed:affiliation |
Laboratoire d'ématologie et de Cytogénétique, Centre Hospitalier Lyon Sud, Pierre-Bénite, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
